期刊文献+

铂类抗肿瘤药物的设计开发进展 被引量:5

Design and development progress of platinum-based anticancer drugs
原文传递
导出
摘要 铂类抗肿瘤药物是临床上使用广泛的化疗药物,具有近40年的研究和使用历史.本文对临床上使用和处于临床研究中的铂类药物进行了简单介绍,总结了进入临床研究阶段被淘汰的铂类药物,针对目前铂类药物所处形势重点介绍了新一代铂类药物的设计开发方法.新一代铂类药物包括修饰和改进的经典构型的Pt(II)配合物、反式Pt(II)配合物、药物前体Pt(IV)配合物、单功能铂配合物、配位饱和的铂配合物和多核铂配合物等.通过列举最新研究成果,分析药物作用机制,提出铂类药物的设计开发方法,让读者了解铂类抗肿瘤药物的发展历程和未来的发展趋势. Platinum-based anticancer drugs which are widely used in clinic have nearly 40 years history of research and application. In this review, we make a brief introduction of platinum-based anticancer drugs which have been used in clinic or still during the clinical trails, and summarized the drugs which were failed in clinical trails. We introduce the design and development methods of new generation platinum-based anticancer drugs consisting of platinum(II) complexes such as modified and improved trans-platinum(II) complexes, platinum(IV) complexes, and mono-functional platinum complexes. Coordination-saturation platinum complexes and multinuclear platinum complexes are discussed emphatically. This review has put forward some design methods of platinum-based anticancer drugs through listing some of the latest research results, and let readers understand the development of platinum-based anticancer drugs and the future direction of development.
出处 《中国科学:化学》 CAS CSCD 北大核心 2015年第7期679-691,共13页 SCIENTIA SINICA Chimica
基金 云南省科技厅重点新产品开发计划(2013BC010)资助
关键词 铂配合物 抗肿瘤药物 新一代铂类药物 设计方法 platinum complex anticancer drugs new generation platinum-based anticancer drugs design method
  • 相关文献

参考文献72

  • 1Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin, 2011, 61 : 69-90.
  • 2Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA CancerJ Clin, 2014, 64:9-29.
  • 3Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W, 3rd, Salner AL, Zelefsky MJ, Aragon-Ching JB, Slovin SF, Wittmann DA, Hoyt MA, Sinibaldi VJ, Chodak G, Pratt-Chapman ML, Cowens-Alvarado RL. American cancer society prostate cancer survivorship care guidelines. CA Cancer J Clin, 2014, 64:225-249.
  • 4Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin, 2014, 64:104-117.
  • 5陈万青,张思维,曾红梅,郑荣寿,邹小农,赵平,吴良有,李光琳,赫捷.中国2010年恶性肿瘤发病与死亡[J].中国肿瘤,2014,23(1):1-10. 被引量:882
  • 6张华吉,郭述金,孙玲,温庆辉,程保.2013年美国FDA批准新药简析[J].中国新药杂志,2014,23(6):619-622. 被引量:10
  • 7Komeda S, Casini A. Next-generation anticancer metallodrugs. Curr Top Med Chem, 2012, 12:219-235.
  • 8Rosenberg BH, Cavalieri LF. Template deoxyribonucleic acid and the control of replication. Nature, 1965, 206:999-1001.
  • 9Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature, 1969, 222: 385-386.
  • 10Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 1989, 37:162-190.

二级参考文献159

  • 1Kiehyka R, Fakhoury J, Moitessier N, et al. Chem. Eur. J., 2008, 14:1145--1154.
  • 2Kieltyka R, Englebienne P, Fakhoury J, et al. J. Am. Chem. Soe., 2008, 130:10040--10041.
  • 3Pennington .l D, Jacobs K M, Sun L, et al. Curr. Pharm. Design, 2007, 13:3368--3377.
  • 4Urig S, Fritz-Wolf K, Reau R, et al. Angew. Chem. Int. Ed., 2006, 45:1881--1886.
  • 5Barnard P J, Bemers-Pdee S J. Coord. Chem. Rev., 2007, 251: 1889--1902.
  • 6Wang Y, He Q Y, Che C M, et al. Proteomics, 2006, 6:131--142.
  • 7Ott I, Schmidt K, Kircher B, et al. J. Med. Chem., 2005, 48 : 622--629.
  • 8Failes TW, CuUinane C, Diakos C I, et al. Chem. Eur. J., 2007, 13 : 2974--2982.
  • 9Timerbaev A R, Hartinger C G, Aleksenko S S, et al. Chem. Rev., 2006, 106:2224--2248.
  • 10Calderone V, Casini A, Mangani S, et al. Angew. Chem. Int. Ed., 2006, 45:1267--1269.

共引文献928

同被引文献205

引证文献5

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部